Russian President Putin States at AI Conference That Human Lifespan of 150 Years is "Very Likely Achievable"
Denis Sekirinsky, Deputy Minister of Science and Education of Russia, announced that scientists are developing the world's first gene therapy drug to slow cellular aging by blocking the RAGE (Receptor for Advanced Glycation End Products) gene. This project is led by the Institute of Biological Aging and Medicine and is part of the "National Project for New Health Technologies" promoted by Putin.
Months ago, Russian President Putin stated at an AI conference that a human lifespan of 150 years is "very likely achievable," but emphasized that this is still not enough. This context is directly related to the long-term pressures of an aging population and declining birth rates in Russia.
Source: Public Information
ABAB AI Insight
This development plan highlights direct intervention at the national level regarding the demographic crisis. Russia has long faced a shrinking workforce and increasing pension burdens, and anti-aging drugs represent a technological pathway to alleviate systemic pressures by extending healthy lifespans. It places biotechnology at the core of national strategy, attempting to reshape population quality through genetic intervention rather than solely relying on immigration or birth incentives.
From a deeper structural perspective, this reflects a potential shift in wealth and power redistribution amid global aging trends. If successful, the drug would alter labor markets, pension systems, and healthcare resource allocation, extending individual production cycles while amplifying the advantages of early-adopting countries in industrial migration. Historically, similar longevity interventions have been accompanied by ethical and inequality controversies: the technological benefits are likely to concentrate among elite classes, further entrenching class stratification.
The event is situated within a long cycle of technology-institution dynamics. Putin's statements at the AI conference and the subsequent acceleration of projects indicate that power centers are binding cutting-edge biotechnology with geopolitical needs. This state-driven model has short-term efficiency in resource concentration but also exposes institutional inertia in handling risks and ethical constraints, ultimately affecting the pricing power and diffusion pathways of global anti-aging technologies.